key: cord-0831640-nhmfbgok
authors: Brown, Richard J. P.; Tegtmeyer, Birthe; Sheldon, Julie; Khera, Tanvi; Anggakusuma,; Todt, Daniel; Vieyres, Gabrielle; Weller, Romy; Joecks, Sebastian; Zhang, Yudi; Sake, Svenja; Bankwitz, Dorothea; Welsch, Kathrin; Ginkel, Corinne; Engelmann, Michael; Gerold, Gisa; Steinmann, Eike; Yuan, Qinggong; Ott, Michael; Vondran, Florian W. R.; Krey, Thomas; Ströh, Luisa J.; Miskey, Csaba; Ivics, Zoltán; Herder, Vanessa; Baumgärtner, Wolfgang; Lauber, Chris; Seifert, Michael; Tarr, Alexander W.; McClure, C. Patrick; Randall, Glenn; Baktash, Yasmine; Ploss, Alexander; Thi, Viet Loan Dao; Michailidis, Eleftherios; Saeed, Mohsan; Verhoye, Lieven; Meuleman, Philip; Goedecke, Natascha; Wirth, Dagmar; Rice, Charles M.; Pietschmann, Thomas
title: Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice
date: 2020-11-04
journal: Sci Adv
DOI: 10.1126/sciadv.abd3233
sha: cbe1a6910b9c77f262d8a0ca2e34be845d0d23ba
doc_id: 831640
cord_uid: nhmfbgok

Hepatitis C virus (HCV) has no animal reservoir, infecting only humans. To investigate species barrier determinants limiting infection of rodents, murine liver complementary DNA library screening was performed, identifying transmembrane proteins Cd302 and Cr1l as potent restrictors of HCV propagation. Combined ectopic expression in human hepatoma cells impeded HCV uptake and cooperatively mediated transcriptional dysregulation of a noncanonical program of immunity genes. Murine hepatocyte expression of both factors was constitutive and not interferon inducible, while differences in liver expression and the ability to restrict HCV were observed between the murine orthologs and their human counterparts. Genetic ablation of endogenous Cd302 expression in human HCV entry factor transgenic mice increased hepatocyte permissiveness for an adapted HCV strain and dysregulated expression of metabolic process and host defense genes. These findings highlight human-mouse differences in liver-intrinsic antiviral immunity and facilitate the development of next-generation murine models for preclinical testing of HCV vaccine candidates.

Hepatitis C virus (HCV) chronically infects 71 million people worldwide, resulting in 400,000 deaths per year (1) . Despite major advances in antiviral treatment, no vaccine for HCV is available, and with ca. 1.75 million new infections in 2015, virus transmission rates remain high (2) . HCV can establish chronic infections in the human liver, causing progressive liver damage and leading to severe complications including cirrhosis and hepatocellular carcinoma. In general, viruses are usually well adapted to their host, and cross-species transmissions can be limited by host factor incompatibilities and restriction fac-tors (3) . Tropism and pathogenesis depend on exploitation of host factors supporting infection and evasion of cellular antiviral mechanisms (4, 5) . HCV naturally infects only humans, preventing studies of progressive immunopathogenesis or preclinical testing of novel therapeutics in an immunocompetent animal model. Recently, in attempts to address this problem, related viruses infecting diverse species have been repurposed as infection models for hepaciviruses (6) (7) (8) (9) in their natural hosts. However, these viruses are substantially divergent from their human-infecting counterpart, HCV, limiting their usefulness for clinical infection research. Previous work only either mCd302 or mCr1l was considerably greater than that observed for human NOS2, a described anti-HCV factor (14) . Combined mCd302/mCr1l expression enhanced the antiviral effect, suggesting that these proteins may act in concert, with RLU counts 200-fold reduced compared to the control cell line (Fig. 1D ). Next, we performed infections of murine restriction factor-expressing cell lines with a panel of R-luc reporter HCV chimeras, encoding core-NS2 from genotypes 1 to 7 and NS3-NS5B from strain JFH-1. These strains encompass the genetic and antigenic diversity apparent in the structural proteins from globally sampled HCV isolates. We observed varied but potent restriction of infection by all HCV genotypes (Fig. 1E ). In general, in agreement with genotype 2a infections, combined mCd302/mCr1l restriction was more potent than either factor alone. Infection of Huh-7.5 cells overexpressing mCd302 and mCr1l (individually or in combination) with nonreporter HCV (strain Jc1) revealed an identical restriction phenotype to that observed with reporter HCV (Fig. 1F) : A marked reduction of both intracellular viral RNA (vRNA, top) or secreted virions (bottom) was apparent at 72 hours post-infection (hpi) when compared to control cells. To confirm that mCd302 and mCr1l also restrict patientderived primary isolates, we ectopically expressed human SEC14L2 in Huh-7.5 cells, which was previously shown to facilitate the propagation of primary HCV isolates in tissue culture (15) . Huh-7.5-SEC14L2 cells supported infection with sera of patients infected with genetically diverse HCV subtypes (1a, 1b, and 3a), which could be suppressed with daclatasvir-an inhibitor of the HCV NS5A phosphoprotein. Combining ectopic SEC14L2 expression with either mCd302 or mCr1l, we observed that both murine factors restrict infection of Huh-7.5 cells with HCV patient isolates (Fig. 1G) .

To investigate the breadth of mCd302 and mCr1l antiviral restriction, we conducted infection assays using a divergent panel of viruses. The related flaviviruses dengue virus (DENV), West Nile virus (WNV), and yellow fever virus (YFV), which are all transmitted by mosquito vectors, were not impaired by mCd302 and mCr1l overexpression. Similarly, infection with human respiratory syncytial virus (hRSV) and a zoonotic strain of the hepatotropic hepatitis E virus (HEV) was not significantly impeded ( fig. S2 ), although a modest effect on HEV replication could be observed. Together, these data indicate that murine Cd302 and Cr1l mediate a strong and cooperative antiviral effect against HCV.

Cd302 and Cr1l coexpression inhibits HCV cell entry Cellular localization of overexpressed mCd302 and mCr1l in Huh-7.5 cells was investigated by flow cytometry and immunofluorescence staining, revealing distribution of both proteins throughout the cytosol and concentration of expression at the plasma membrane ( Fig. 2A) . To investigate whether HCV infection was impeded at an early stage of the viral life cycle, we infected cells with lentiviral pseudoparticles decorated with HCV envelope proteins (HCVpps) from different strains (Con1 and UKN2B2.8) and compared them to HCVcc infections (Fig. 2B) . These data revealed an entry-specific effect only for mCd302 but not for mCr1l alone. However, entryspecific restriction of mCd302 was further enhanced by coexpression with mCr1l, indicating that both factors act cooperatively to impede HCVpp entry. The level of restriction on HCVpp entry was 10-to 20-fold less than that observed for HCVcc infection. This could be due to differences between authentic virions and HCVpps including differences in envelope glycoprotein membrane incorporation, envelope lipid composition, N-linked glycosylation, lipoprotein Cell lines ectopically expressing the indicated factors, with and without SEC14L2 coexpression, were infected with primary isolates of the indicated subtypes. Bars represent means of n = 2 technical replicates + SEM. DVR, daclatasvir. ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05. association, or the absence of secondary rounds of infection for HCVpps. Alternatively, the observed differences between HCVcc and HCVpp restriction may be due to additional targeting of postentry stages, which are not recapitulated in the pseudoparticle infection assay.

To probe whether mCd302 and mCr1l impede HCV cell surface trafficking in polarized cells, we used a single-particle tracking assay. In this assay, Matrigel-polarized Huh-7.5 hepatoma cell organoids, which recapitulate the polarization of hepatocytes in vivo, were inoculated with purified, DiD-labeled HCV particles (16) . Organoids transduced with an EMPTY vector, mCd302, or mCr1l/ mCd302 were inoculated with DiD-HCV at 4°C; unbound particles were washed away; and cells were shifted to 37°C to enable real-time visualization of bound particle trafficking to the tight junction (Fig. 2C, top) . Organoids were fixed at multiple time points (minutes post temperature shift: mpts) and stained for ZO-1, a tight junction marker protein, DiD-HCV, and organoid nuclei. EMPTY vector cells showed a maximum colocalization of HCV with ZO-1 at 90 mpts consistent with previous data (16) . However, organoids expressing mCd302 or mCr1l/mCd302 displayed significantly lower colocalization at 0 and 90 mpts (Fig. 2C, bottom) . These data suggest a defect in trafficking to the tight junction, a crucial step in the HCV uptake process. Furthermore, while colocalization with control organoids drops off at 360 mpts, indicating that particles have internalized, DiD-HCV particles in mCr1l/mCd302 organoids maintained colocalization with ZO-1, suggesting a possible internalization defect. Together, these data imply that mCd302 and mCr1l mediate their anti-HCV effect, in part, by disrupting steps of the complex entry cascade.

To investigate whether surface-expressed mCd302 and mCr1l proteins bind directly to HCV particles, we incubated HCVcc particles with either untransfected CHO-745 cells or CHO-745 cells transfected with mCd302, mCr1l, or mCr1l/mCd302 plasmids. CHO-745 cells were used for the HCV attachment assay, because they lack endogenous expression of canonical HCV entry factors and are deficient in synthesis of proteoglycans due to a defect in xylosyltransferase activity, thus reducing nonspecific background binding. We used CHO-745 cells expressing the human HCV entry receptor SCARB1, which is known to bind virions directly, as a control (17) (18) (19) . HCV was incubated with cells, followed by washing, RNA extraction, and quantification cell-bound vRNA by reverse transcription quantitative polymerase chain reaction (RT-qPCR) (Fig. 2D, left) . Similar to cells expressing SCARB1, murine restriction factor expressingcells exhibited ~3-fold more surface-bound HCV RNA when compared to untransfected CHO-745 cells, suggesting that both mCd302 and mCr1l can directly bind HCV, comparable to the levels seen for the HCV entry factor SCARB1. Surface localization of ectopically expressed factors was confirmed by flow cytometry. While cell surface localization of murine factors in CHO-745 cells was lower than that observed for human SCARB2, surface detection was apparent for both Cd302 and Cr1l (Fig. 2D, right) .

The murine Cd302 gene encodes a 228-amino acid type I transmembrane protein containing a SP (SP; 20 amino acids), a CTLD (CTLD; 132 amino acids), a spacer region (S; 13 amino acids), a TM (TM; 24 amino acids), and a CPT (CPT; 39 amino acids) (20, 21) . To determine the mCd302 domain(s) important for the observed anti-HCV restriction, we initially generated two mCd302 domain deletion constructs: CTLD and CPT. While deletion of the CTLD partially ablated the restriction phenotype, truncation of the CPT completely ablated the inhibition of HCV infection (Fig. 2E, left) . Expression and cell surface localization of the CPT mutant protein were largely unaffected ( fig. S3 ). In contrast, as the -mCd302 antibody binds to the CTLD, the ability to detect this mutant protein was lost ( fig. S3 ). Putative functional residues/ motifs in the mCd302 CPT include a single cysteine residue (C213), which could serve as a putative palmitoylation site; two tyrosine residues (Y209 and Y223), which could be phosphorylated and involved in downstream signaling; and an EEDE acidic patch (219 to 222), which could serve as an internalization motif. Mutation/deletion of any of these critical residues completely destroyed the HCV restriction phenotype of Cd302 (Fig. 2E, right) , while protein expression was unaffected ( fig. S3 ). Cell surface expression of Cd302 CPT mutants was reduced compared to Cd302 wild type (WT), although still detectable ( fig. S3 ).

The murine Cr1l gene encodes a 440-amino acid transmembrane protein containing an SP (40 amino acids), an ED (ED; 310 amino acids), a TM (36 amino acids), and a CPT (54 amino acids). In contrast to mCd302, CPT of mCr1l had no effect on the capacity to restrict HCV infection, while deletion of the transmembrane domain and CPT together (TM + CPT) disrupted plasma membrane incorporation and ablated HCV restriction (Fig. 2F ). Together, these data identified the domains in each protein critical for the anti-HCV phenotype. Both the C-type lectin domain and the cytoplasmic tail are required for mCd302 to restrict HCV, with the cytoplasmic tail integral for restriction. In contrast, the ectodomain and membrane incorporation are required for mCr1l restriction.

Next, we explored whether mCr1l/mCd302 restriction is dependent on IFN signaling. As both type I and type III IFNs signal via the Janus kinase-signal transducer and activator of transcription 1 (JAK/STAT1) signaling cascade, we treated ectopically expressing cell lines with the JAK/STAT inhibitor ruxolitinib, IFN (IFN, subtype 2a), or a combination of both, followed by infection with HCV. JAK/STAT inhibition alone could not ablate HCV restriction in cells overexpressing mCd302/mCr1l, although the antiviral effect of IFN could be ablated and the infection phenotype could be rescued (Fig. 3A) . These data indicate that murine mCd302/mCr1l restriction occurs independently of the JAK/STAT pathway.

To further investigate the mechanism of restriction, we used transcriptional profiling of Huh-7.5 cell lines ectopically expressing murine restriction factors (mCd302, mCr1l, and mCd302/mCr1l) and compared dysregulated genes signatures to control cell lines (EMPTY and mCd302CPT), which are highly permissive for HCV infection. Levels of critical HCV entry factors SCARBI, CD81, OCLN, and CLDN1 mRNA and cell surface protein expression were comparable in permissive and restricting cell lines. Likewise, mRNA levels of replication or assembly cofactor mRNAs PI4KA, PPIA, and APOE were also comparable ( fig. S4 ). Analysis of differentially expressed genes (DEGs) in each cell line (when compared to the EMPTY cell line that is highly permissive for HCV infection) showed that HCV-permissive mCd302CPT cell transcriptomes were comparable to EMPTY cells, with relatively few DEGs detected (Fig. 3B ). Of note, we observed increasing numbers of DEGs in mCr1l, mCd302, and mCr1l/mCd302 cells, respectively, suggesting an additive or cooperative effect of overexpressing both factors in parallel, with ~200 DEGs apparent in mCr1l/mCd302 cells (Fig. 3B ). To investigate whether these two proteins physically interact, we performed immunoprecipitations. Coimmunoprecipitation of mCr1l with hemagglutinin (HA)-tagged mCd302 confirmed the mCd302-mCr1l interaction, indicating that both factors might bind each other and act cooperatively to mediate their combined potent anti-HCV phenotype (Fig. 3C ). Stringent analyses of mCr1l-and mCd302-specific DEGs [false discovery rate (FDR) P <0.05, only transcripts with RPKM >1 included] revealed a program of dysregulated genes in mCd302 cells, which was further enhanced by coexpression with mCr1l (Fig. 3D ). Cells ectopically expressing mCd302CPT exhibited minimal DEGs, suggesting that mCr1l/mCd302-dependent transcriptional changes are dependent on the CPT of mCd302. In many cases, ectopic expression of mCr1l and mCd302 individually up-regulated the same target gene and concomitant expression of both mCr1l/mCd302 that further boosted expression of these targets (e.g., ACY3, ALPI, C19orf33, and TFF1), underpinning cooperativity between mCr1l and mCd302 in transcriptional regulation of cellular genes. The majority of mCr1l/ mCd302-specific DEGs (88 of 122) represented IFN-regulated genes (IRGs) (22) . These data indicate that overexpression of mCr1l/ mCd302 results in the dysregulation of a specific subset of antiviral genes, which likely contributes an intrinsic anti-HCV phenotype.

Cd302 and Cr1l are constitutively expressed in murine hepatocytes and not induced by IFN We next investigated whether murine hepatocytes express these identified restriction factors. Transcriptional profiling of total mouse livers and plated primary mouse hepatocytes (PMHs) from multiple standard laboratory strains revealed abundant expression of mCd302 and mCr1l mRNA transcripts, comparable to well-characterized hepatocyte-specific transcripts (Fig. 4A ). In contrast, brain-or lung-specific mRNAs were either barely detectable or completely absent. We observed constitutive expression of mCd302 and mCr1l proteins in primary murine hepatocytes by immunofluorescence 

confocal microscopy, with distribution throughout the cytosol and a notable fraction of mCr1l localized to a perinuclear compartment (Fig. 4B ). In situ staining of formalin fixed paraffin embedded (FFPE) mouse liver slices confirmed mCr1l membranous localization in hepatocytes ( Fig. 4C ) and, in agreement with this observation, flow cytometry of nonpermeabilized mouse hepatocytes revealed a sub-fraction of both proteins localized to the cell surface (Fig. 4D ). Together, these data confirm constitutive expression of mCd302 and mCr1l mRNAs and encoded protein in murine livers and hepatocytes, the analogous target cells for HCV infection in humans. Antiviral responses to RNA viruses in hepatocytes are mediated by at least two distinct, non-overlapping sensing pathways: retinoic The basal lineage leading to mice/rats is highlighted in red. The marsupial Cd302 sequence from the Tasmanian devil was used as an outgroup. Right: Protein cartoon denotes the relative functional domains of mCd302 with the position of coding mutations unique to the rat/mouse specific lineage highlighted below. acid inducible gene I (RIG-I) and Toll-like receptor 3 (TLR3) (23) . To determine whether mCd302 or mCr1l expression is modulated by either pathway, we treated murine primary hepatocytes with either IFN2a or the double-stranded RNA mimic polyinosinic:polycytidyl acid (polyI:C). Compared to control IRGs, we did not detect dysregulation of mCd302 or mCr1l mRNAs, indicating that their expression is constitutive and regulated by neither RIG-I nor TLR3 sensing pathways (Fig. 4E) .

The human and rodent lineages diverged 80 to 90 million years ago (24) , and infection of immunocompetent mice with HCV is not possible. The Cd302 gene is conserved throughout mammalian evolution, and phylogenetic analysis of Cd302 coding sequences from representative mammalian species revealed reconstruction of the superordinal groupings predicted using multikilobase genomic loci (24) . However, inconsistent with the organismal phylogeny, the positioning of the rat/mouse orthologs with other rodent species (guinea pig) was not supported, with these two species located antecedent to the placental grouping (Fig. 4F, left) . This basal positioning of rat/mouse orthologs was supported by significant bootstrap values. Closer inspection revealed fixation of nine unique nonsynonymous mutations on the rat-mouse lineage, distributed throughout the protein but concentrated in cytoplasmic tail (Fig. 4F , right). Together, these data indicate a unique evolutionary trajectory for rat/murine Cd302, with the fixation of multiple mutations on the rat:mouse branch giving rise to the incongruence between organismal and Cd302 phylogenies. This likely represents the signature of selection in response to pressure from pathogens and/or the possible acquisition of a novel biological function (e.g., antiviral restriction) or interaction partner (e.g., mCr1l). Phylogenetic analysis of mammalian Cr1l was not possible due to high levels of sequence divergence including indels (see Fig. 5B ), coupled with the absence of a Cr1l ortholog in many mammal species.

Human hepatocytes lack CR1L mRNA expression but express CD302, limiting HCV infection To explore whether CD302 and/or CR1L may have broader relevance for HCV permissiveness in humans, we aligned the human and murine protein orthologs of both factors. The hCD302:mCd302 alignment revealed ~75% amino acid conservation, with hydrophobicity plotting identifying putative conserved transmembrane domains, implying membrane incorporation in both species (Fig. 5A ). Differences between human and mouse were concentrated in the cytoplasmic tail domain. In contrast, hCR1L:mCr1l proteins shared only ~35% sequence identity, with large differences observed in the size of the translated protein. Hydrophobicity plotting identified a putative transmembrane region in murine Cr1l, although this domain was absent in human CR1L (Fig. 5B) .

To investigate whether mRNA transcript abundance in hepatocytes is conserved between mice and humans, we conducted transcriptomic profiling of plated PHHs from multiple donors. While hCD302 transcripts were readily detected at similar levels to that observed in mice, hCR1L transcripts were virtually undetectable or completely absent, comparable to brain-or lung-specific mRNAs (Fig. 5C ). Together, these data confirm constitutive expression of hCD302 mRNA in PHHs but the absence of hCR1L, suggesting that the combined potent and cooperative anti-HCV restriction provided by coexpression of both factors in mice is absent in the human liver. To test the human orthologs' ability to restrict HCV infection, we ectopically expressed hCD302 and hCR1L in Huh-7.5 cells followed by infection with R-luc reporter HCV. Comparable to mCd302, we observed a potent reduction of intracellular RLU accumulation over a 4-to 96-hour time course for hCD302 (Fig. 5D ). However, hCR1L mediated no effect on the ability of HCV to infect hepatoma cells. To determine whether expression of hCD302 in PHHs is modulated by the RIG-I or TLR3 sensing pathway, we treated PHHs with either IFN2a or polyI:C. Similar to mouse hepatocytes, we did not detect a dysregulation of hCD302 mRNA when compared to control genes, indicating that its expression is steady state and not regulated by either the RIG-I or TLR3 sensing pathways (Fig. 5E ). The inability of the human ortholog of CR1L to restrict HCV, combined with an absence of CR1L mRNA in PHHs, highlights the differences between human and mouse with respect to intrinsic liver defenses: The combined cooperative antiviral restriction provided by both factors is absent in humans. Nonetheless, hCD302 alone was able to restrict HCV infection, which warrants further investigation. C-type lectins make up a large superfamily of proteins with diverse functions. A unifying feature of this group of proteins is the CTLD fold, which is characterized by a double-loop structure that is stabilized by conserved disulfide bridges at the bases of these loops. The presence or absence of the so-called long loop region is used to divide CTLDs in two groups: Classical CTLDs (e.g., dendritic cellspecific intercellular adhesion molecule-3-grabbing non-integrin: DC-SIGN) have a long loop region, which is absent in the more compact CTLDs (e.g., human CD44). The long loop region is involved in Ca 2+ -dependent carbohydrate binding and also in the binding of other ligands (25) . Recently, the nuclear magnetic resonance (NMR) structure of the hCD302 extracellular domain was solved, showing that it comprises a canonical CTLD fold with a long loop region (Fig. 5F , right) (26) . Superposition of an mCd302 CTLD homology model onto the CTLD structure of hCD302 revealed a large number of surface residues conserved between mouse and human CTLDs (Fig. 5F, left) . This finding suggests conservation of ligand specificity between the mouse and human orthologs. In contrast, alignment of CPT regions highlights differences between human and mouse and may point to potential differences in downstream signaling between the species (Fig. 5F , bottom).

The minimal requirements for HCV entry into murine hepatocytes are the ectopic expression of human entry factors OCLN and CD81 (12) . Consequently, we generated humanized hOC hep mice, which conditionally express human CD81 and OCLN in hepatocytes (hOCLN +/− hCD81 +/− ). To examine the relevance of endogenous Cd302 and Cr1l expression for HCV restriction, we explored whether knockdown of mCd302 and mCr1l in plated primary hOC hep cells modulated the cellular response to infection and increased HCV permissiveness. To this end, we silenced mCd302 and mCr1l mRNA in plated hOC hep , followed by HCV infection (strain Jc1) and transcriptional profiling. The antiviral response to HCV infection was greater in plated hOC hep previously treated with mCd302 and mCr1l targeting small interfering RNAs (siRNAs) when compared to hepatocytes transfected with control siRNAs (Fig. 6A) . We did not observe this trend in PMH from a WT mouse lacking the human entry factors, indicating an HCV entry-associated process. These data suggested that mCd302 and mCr1l silencing facilitates more efficient HCV entry into murine hepatocytes, resulting in a concomitant increase in the magnitude of the murine hepatocyte antiviral response. However, we did not observe subsequent viral replication in plated hOC hep . In contrast, siRNA targeting of ectopically expressed mCd302, mCr1l, or mCd302 and mCr1l in Huh-7.5 cells increased Jc1 replication (fig. S5 ). To overcome the observed block on HCV replication in murine hepatocytes, we compared fitness of parental HCV (strain Jc1) with an HCV population derived from Jc1 after 100 passages (p100pop) in Huh-7.5 cells, which exhibits enhanced replicative fitness and partial resistance to IFN (27) . Infection of mouse liver tumor (MLT) cells that ectopically express five human factors (CD81, SCARB1, CLDN1, OCLN, and APOE: 5H) coupled with blunted innate immune signaling due to ablation of mitochondrial antiviral-signaling protein (MAVS) expression (MLT/ MAVS −/− 5H) (10) revealed significantly enhanced permissiveness to p100pop when compared to parental Jc1 (Fig. 6B) . Suppression of p100pop replication in MLT/MAVS −/− 5H was also demonstrated using teleprevir, an HCV NS3 protease inhibitor (Fig. 6B ). This enhanced replicative fitness was correlated with 14 nonsynonymous mutations with >50% population frequency distributed throughout the p100pop open reading frame (ORF) (Fig. 6C) . Although p100pop exhibits enhanced replicative capacity in murine liver cells, this strain was susceptible to mCd302/mCr1l restriction, albeit to a lesser extent than parental Jc1 ( fig. S6 ).

Silencing of mCd302 and mCr1l was effective in humanized mouse hepatocytes, leading to increased HCV uptake and a concomitant increase in innate cellular responses (Fig. 6A) . However, because of high intrinsic expression, targeted mRNAs encoding functional mCd302 and mCr1l were still detected. To overcome this limitation, we deleted Exon 1 of the mCd302 locus in hOC hep mice using CRISPR-Cas9 technology. Comparative Western blotting of primary hepatocytes from hOC hep and hOC hep Cd302 −/− mice revealed complete ablation of functional Cd302 protein expression (Fig. 6D) . Unfortunately, mCr1l −/− knockout mice were not viable due to an embryonically lethal phenotype (28) . To determine whether mCd302 deletion modulated the intrinsic murine hepatocyte transcriptome, we performed global RNA-seq profiling on primary hepatocytes isolated from hOC hep and hOC hep Cd302 −/− mice. These analyses revealed 289 significant DEGs in hepatocytes from hOC hep Cd302 −/− mice when compared to control hOC hep mice, confirming a role for mCd302 in the regulation of constitutive gene expression levels in murine hepatocytes. Gene Ontology (GO) analyses revealed significant and overlapping dysregulation of genes associated with cellular defense and the inflammatory response, in addition to modulation of gene expression associated with hepatocyte metabolic processing ( fig. S7, left) . Analogous to overexpression of mouse Cd302/Cr1l in human cell lines where antiviral genes were generally up-regulated, ablation of endogenous Cd302 expression in mouse hepatocytes resulted in down-regulation of a subset of genes involved in virus defense and the inflammatory response (e.g., Apobec1, Isg20, Oasl1, Ccl7, and Cxcl9) ( fig. S7, top right) . In addition, dysregulation of genes associated with metabolic processing of lipids and fatty acids was also affected (e.g., Fabp4, Fabp5, and Plin5) (fig. S7, bottom right) . A total of 159 of 289 DEGs were classified as IRGs.

To determine the effect of endogenous Cd302 knockout on HCV permissiveness, we infected either plated primary hepatocytes isolated from hOC hep or hOC hep Cd302 −/− mice with p100pop, blunting IFN responses with ruxolitinib. At 4 hpi, we detected higher levels of cell-associated HCV core protein in hOC hep Cd302 −/− hepatocytes when compared to hOC hep controls (Fig. 6E, left) . Cell-associated HCV core protein was reduced at 24 hpi likely due to vigorous IFN-dependent antiviral defenses. However, a significant difference was apparent between hepatocytes isolated from hOC hep Cd302 −/− and hOC hep mice, with two-to fourfold greater cell-associated core detected, which could be further enhanced by JAK/STAT inhibition (Fig. 6E, right) . These data suggested that ablation of endogenous Cd302 expression in humanized mouse hepatocytes increased infection by human-tropic HCV. Building on these data, we performed a time course comparison, infecting hepatocytes isolated from both hOC hep and hOC hep Cd302 −/− mice with either Jc1 or p100pop after JAK/STAT inhibition, and monitored de novo virus production at 24 to 144 hpi. No differences in virion release were observed between hepatocytes from hOC hep and hOC hep Cd302 −/− mice infected with Jc1, with limited de novo HCV production detected (Fig. 6F,  left) . In contrast and despite differences observed between individual animals, de novo p100pop production was demonstrably increased in hepatocytes isolated from hOC hep Cd302 −/− mice when compared to parallel control hepatocytes from hOC hep mice at 48 to 144 hpi, with up to 50-fold greater mean virus production observed (Fig. 6F , right). To investigate whether this observation could be replicated in vivo, we performed intrasplenic inoculation of hOC hep or hOC hep Cd302 −/− mice with p100pop, with continued oral administration of ruxolitinib to suppress antiviral defenses mediated by JAK/STAT signaling (Fig. 6G ). Serum and liver vRNA were assessed at 72 and 120 hpi. No differences were observed in serum vRNA between hOC hep and hOC hep Cd302 −/− mice at either time point, indicating a potential block on virus release in the murine liver. In contrast, at 120 hpi, mean liver-resident vRNA was ca. 7-fold higher in hOC hep Cd302 −/− mice compared to hOC hep animals, and only hOC hep Cd302 −/− mice displayed a significant increase of liver-resident virus load from 72 to 120 hpi (Fig. 6G ). In summary, these data confirm that Cd302 contributes to the species barrier limiting HCV infection of murine hepatocytes, both in vivo and ex vivo.

The tolerogenic environment of the liver represents an attractive replication environment for pathogens enabling the establishment of chronic infection by HCV. Using cDNA library screening, we identified a lectin and a complement receptor, Cd302 and Cr1l, as previously unreported species barrier determinants contributing to HCV restriction in the murine liver. Our data demonstrate that mCd302 and mCr1l expression is constitutive in murine hepatocytes and not inducible by IFN: These factors mediate protection independently of the IFN system. We observed differences in liver expression and the ability to restrict HCV between the murine orthologs and their human counterparts. The unique evolutionary trajectory of mouse:rat Cd302, which is largely due to differences concentrated in the short cytoplasmic tail, coupled with the lack of an interaction partner (Cr1l) to amplify any potential signal in humans, suggests that murine Cd302 has acquired a unique or enhanced antiviral function when compared to its human ortholog. Rodents (similar to bats) have high population densities in the wild and consequently represent reservoirs for many pathogens. Therefore, it is possible that mice might have evolved novel or enhanced antiviral strategies to cope with these more frequent pathogen exposures when compared to humans. Despite the differences observed between humans and mice, human CD302 mRNA was also abundant in PHHs, and ectopic expression of human CD302 in hepatoma cells mediated an anti-HCV phenotype. Although outside the scope of this investigation, determining whether different allelic variants or differing hCD302 expression levels in the livers of HCV-infected patients is correlated with disease outcome (e.g., severity of liver disease or viral clearance versus persistence) is currently the subject of further investigation.

Mechanistically, our data support a model where the murine transmembrane proteins Cd302 and Cr1l interact with each other and with virions to impede HCV cell entry. Competition with virus binding to canonical entry factors may impede virus trafficking to tight junctions and, in turn, productive infection. In addition, ectopic expression of murine factors in human hepatoma cells resulted in the cooperative induction of a noncanonical transcriptional program. Moreover, modulation of the intrinsic murine hepatocyte transcriptome was observed upon Cas9 disruption of endogenous Cd302 expression. To further dissect these observations, we used ingenuity pathway analysis (IPA) to compare gene expression changes observed between Huh-7.5 and Huh-7.5 [mCd302/mCr1l] cells with those observed between humanized hOC hep and hOC hep Cd302 −/− PMHs. Modulation of mCd302 expression targeted common pathways in human and mouse liver cells: 16 significantly enriched canonical pathways were shared between both systems including four pathways associated with related nuclear receptors (NRs) (fig. S8A ). NRs are known to regulate transcriptional programs that control host metabolic processes including lipid metabolism. In addition, NRs have been implicated in host-virus interactions, modulating susceptibility to both DNA and RNA virus infections (29) . NRs have been shown to control both pro-and antiviral metabolic responses to HCV in PHHs (30) . The top hit in both the human and mouse systems represents an NR pathway "LPS/IL-1 mediated inhibition of retinoid X receptor (RXR) function" that influences downstream lipid and fatty acid metabolism. Detailed inspection of shared NR pathways identified significantly dysregulated molecules at multiple pathway stages and contained shared and distinct molecules in both systems ( fig. S8B ). Corresponding changes in gene expression for targeted pathways in both systems highlights opposing transcriptional dysregulation of gene subsets in these analogous in vitro and ex vivo systems ( fig. S8C ). Thus, in both human overexpression and in mouse knockout systems, gain or loss of Cd302 expression influences RXR NR signaling: RXR-dependent genes and their roles in lipid and fatty acid metabolism likely contribute to the resulting antiviral state, as the HCV life cycle is tightly coupled to lipid and fatty acid metabolism.

Cas9 disruption of Cd302 expression in murine hepatocytes, humanized for productive HCV entry, increased permissiveness for an adapted HCV population both ex vivo and in vivo. We demonstrate that p100pop, an HCV population that developed enhanced replication fitness and partial IFN resistance in human cells, also exhibits enhanced fitness in humanized mouse liver cell lines and in humanized PMHs when compared to its parent virus. The enhancement of HCV permissiveness mediated by ablation of Cd302 liver expression in mice was only detectable when infection experiments were performed using p100pop, pointing to additional uncharacterized barriers to efficient HCV propagation in the murine liver. These barriers could represent missing or incompatible human cofactors-or additional murine restriction factors targeting HCV. It is likely that the enhanced replication fitness and reduced IFN sensitivity of p100pop enables a partial overcoming of these additional replication blocks that is not achieved by nonadapted strains. Therefore, p100pop represents a good starting point for development of more robust HCV mouse models, and stepwise adaptation of HCV to complete its full replication cycle in murine hepatocytes may also be possible. However, for the purposes of HCV vaccine development, these adapted viruses should retain the key attributes of strains that infect humans, e.g., receptor usage and immunogenicity.

The murine Cd302 gene is expressed in various myeloid cell types and different murine tissues, most prominently in the liver (20, 21) . While a role in regulating myeloid cell migration was previously reported, the functional importance of hepatocyte-expressed mCd302 remained elusive until now. Lectins expressed in myeloid cells play important roles in immune defenses (31) . They recognize pathogens via their CTLDs and trigger responses such as endocytosis, phagocytosis, and release of pro-or anti-inflammatory cytokines. Moreover, the complement system is essential for pathogen clearance. Here, we report an unexpected cooperation between a hepatocyte-expressed lectin and a complement receptor in mice. This work highlights convergence of lectin and complement systems for shaping liver intrinsic immunity and draws attention to a complex antiviral mechanism involving entry inhibition and metabolic reprogramming. Combining humanization of murine hepatocytes with ablation of a constitutively expressed antiviral defense system-the mCd302/mCr1l axis-and using an adapted HCV population with enhanced replication capacity in murine cells opens new avenues for the development of more robust HCV mouse models. Such a model will be of high value for development and safety testing of prophylactic vaccines to complement existing therapies for global control of and ultimate eradication of the HCV disease burden.

To generate a Mouse IFN-Induced Liver Library (MIILL), a single mouse was injected with IFN and euthanized at 4 hours post IFN induction. The liver was homogenized in TRIzol reagent (Invitrogen), and total RNA was extracted. The PolyA + component of the total RNA was enriched using an Oligotex mRNA kit (QIAGEN). Using components from a SMART cDNA Library Construction Kit (Clontech), mRNA was reverse-transcribed into cDNA and sizefractionated before ligation into the lentiviral vector pV1. Ligated fractions were electroporated into ElectroMAX DH5 (Invitrogen) cells according to the manufacturer's specifications, and resulting colonies were sequenced to ascertain the library quality. Ligated fractions that contained high percentages of diverse full-length mouse ORFs were pooled and electroporated before solid phase amplification in approximately 8 liters of medium. Before solid phase amplification, the MIILL contained 4 × 10 6 independent clones. After solid phase amplification, the pV1 MIILL was extracted from transformed bacteria using a Maxiprep protocol (Macherey Nagel), aliquoted, and stored at −20°C. The library was packaged into VSV-G-enveloped psuedoparticles via three-plasmid transfection into 293T cells. VSV-G, HIV-1gag/pol, and pV1 MIILL plasmids were transfected in equimolar amounts using Lipofectamine 2000 (Invitrogen), and supernatants were harvested at 24 and 48 hours after sodium butyrate induction. Titers of MIILLpps were calculated via median tissue culture infectious dose (TCID 50 ) limiting dilution onto HeLa-TZMbl cells. Cells were fixed and stained 72 hpi, and MIILLpps were aliquoted and stored at −80°C. Permissiveness of different cell lines for MIILLpp transduction was determined via fluorescence-activated cell sorting (FACS) using pV1 green fluorescent protein-containing pseudoparticles. We delivered our MIILL (one to two particles per cell) to highly permissive n4mBid hepatoma cells. These cells are modified Huh-7.5 cells, which undergo programmed cell death upon HCV replication (13) . Iterative rounds of selection were performed with WT HCV [Jc1: multiplicity of infection (MOI) 50], and surviving cells were expanded. Permissiveness to HCV/coronavirus (CoV) infection was assessed using R-luc reporter viruses.

Total RNA from primary cells and cell lines was extracted using a NucleoSpin RNA kit (Macherey Nagel) or TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNA quality checking was performed using an Agilent Bioanalyzer, and sequencing libraries were generated using a ScriptSeqv2 kit (Illumina) according to the manufacturer's instructions. RNA-seq was performed using the Illumina HiSeq 2500 or NovaSeq platforms. Transcriptomic analyses were performed using CLC Genomics Workbench (QIAGEN). Raw FASTQ files were mapped against the hg19 human or mm9 Mus musculus reference genomes with annotated gene and mRNA tracks. Gene expression was calculated for individual transcripts as RPKM, and identification of DEGs was performed. GO analyses were conducted using the GO resource (http://geneontology.org/). Significantly enriched GO categories were identified using the PANTHER Classification system (http://pantherdb.org/). P values for GO categories were adjusted for multiple testing using the Bonferroni correction.

Isolated vRNA was used for Illumina library preparation using a modified protocol of the NNSR priming method (32) . Briefly, for the RT, 5 l of RNA and 100 pmol NNSR_RT primer (gctcttccgatctct-NNNNNN) were heat denatured at 65°C for 5 min and chilled on ice. The reactions were supplemented with first-strand synthesis buffer, 10 mM dithiothreitol, 0.05 mM deoxynucleotide triphosphates (dNTPs), 20 units of RiboLock ribonuclease (RNase) inhibitor, and 200 units of Superscript III reverse transcriptase (Thermo Fisher Scientific). Volumes were standardized to 20 l, and reactions were incubated at 45°C for 30 min followed by heat inactivation at 70°C for 15 min. The nucleic acids were purified with magnetic beads, and the RNA was digested with RNase H [New England Biolabs (NEB)] for 20 min at 37°C. After bead purification, cDNA samples were subjected to second-strand synthesis at 37°C for 30 min in a 50-l final reaction volume containing the following: NEB buffer 2, 0.125 mM dNTPs, 5 units of 3′-5′exo-Klenow Fragment (NEB), and 200 pmol NNSR-2 primer (gctcttccgatctgaNNNNNN). After magnetic bead purification, the double-stranded cDNA served as the template for PCR amplification to obtain the barcoded Illumina libraries. The PCRs were performed using the NEBNext Ultra II Master Mix (NEB) containing 25 pmol NNSRnest_ind_N (caagcagaagacggcatacgagat-NNNNNNgtgactggagttcagacgtgtgctcttccgatctga) and NNSR_Illumina (aatgatacggcgaccaccgagatctacactctttccctacacgacgctcttccgatctct) primers, each using the following cycling conditions: 98°C for 10 s; 5 cycles of 98°C for 10 s, 55°C for 30 s, and 68°C for 30 s; and 15 cycles of 98°C for 10 s, 65°C for 30 s, and 68°C for 30 s. The resulting 300-to 700-base pair (bp) DNA smears were isolated from 1.5% agarose gels with the Zymoclean Gel DNA Recovery Kit (Zymo Research), quantified with qPCR using the NEBNext Library Quant Kit for Illumina (NEB), and sequenced on a MiSeq instrument with a paired-end 2 × 300 setting.

For ectopic expression of human or murine genes, gBlock gene fragments were ordered (Integrated DNA Technologies) and cloned into the lentiviral vector pWPI (Addgene) via restriction cloning (encoding either blasticidin or puromycin resistance genes). Correct orientation and nucleotide sequences of inserts were verified by Sanger sequencing (GATC). Lentiviral plasmids were packaged into VSV-G-enveloped pseudoparticles via three-plasmid transfection into 293T cells. VSV-G, HIV-1gag/pol, and pWPI plasmids were transfected in equimolar amounts using Lipofectamine 2000 (Invitrogen), and supernatants were harvested at 24 and 48 hours after sodium butyrate induction. Pooled supernatants were filtered (45-m pores) and used to transduce 2 × 10 5 Huh-7.5 cells. Seventy-two hours after transduction, selection markers were added to media, and surviving cells were expanded.

All cancer cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with nonessential amino acids (Invitrogen), 2 mM l-glutamine (Invitrogen), and 10% fetal calf serum (FCS) (PAA Laboratories GmbH). For selection of lentiviral transduced cell lines, blasticidin (5 g/ml; Invivogen) or puromycin (2 g/ml; Sigma-Aldrich) was added. To induce polarization, cells were trypsinized and resuspended in DMEM + 10% fetal bovine serum (FBS) for a final concentration of 1 × 10 5 cells/ml. Thawed Matrigel (Growth Factor Reduced, Phenol Red-free; Sigma-Aldrich) and cells were combined in equal parts, seeded onto coverslips in 24well plates (75 l per well), and then incubated at 37°C until polymerized. DMEM + 10% FBS was added to each well, and cells were cultured for 7 days, changing the media every other day.

WT, p100pop (provided as a gift from E. Domingo, Madrid, Spain), and R-luc and F-luc reporter HCV viruses were produced as previously described. Human CoV 229E R-luc reporter virus was provided as a gift from V. Theil (Bern, Switzerland). For DiD labeling, HCV stocks were concentrated using PEG (polyethylene glycol 8000; Thermo Fisher Scientific) precipitation resuspended in serum-free media and then labeled with 5 l of DiD (Invitrogen) per 1-ml concentrated virus for 90 min. The virus was then added to a 10 to 60% weight/volume iodixanol gradient (OptiPrep, Sigma-Aldrich) and centrifuged for 16.5 hours at 34,000 rpm (4°C). The resulting gradient was separated into 1-ml fractions; each was assayed for specific infectivity (33) . Fractions with acceptable specific infectivity (<10) were purified via Amicon Ultra 100K filters (Millipore). Huh-7.5 cells stably expressing SEC14L2 and murine restriction factors were infected with serum from acute-phase or post-transplant patients with HCV as previously described (15) . Briefly, cells were seeded into 24-well plates at a density of 50,000 cells per well and grown overnight. The cells were then infected with 25 l of patient serum diluted in 500 l of DMEM containing 10% FBS, 1× non-essential amino acids (NEAA), and epidermal growth factor (EGF; 50 ng/ml). After overnight incubation with serum, cells were rinsed twice with 1× phosphate-buffered saline (PBS) and fed with 500 l of fresh medium containing 10% FBS, 1× NEAA, and EGF (50 ng/ml). Two days later, the cells were transferred to the 12-well plates and grown for another 3 days before they were harvested for RT-qPCR.

HEV constructs based on the genotype 3 Kernow C1 strain p6, S10-3 cells, and anti-ORF2 antibody were a gift from S. Emerson, National Institutes of Health. To prepare the vRNA for transfection, HEV plasmids p6, p6Gluc, and p6Gluc/GAD active site mutant (34) were linearized with the restriction enzyme Mlu I, and in vitro transcription was performed using the mMESSAGE mMACHINE Kit (Life Technologies). Two hundred nanograms of in vitro-transcribed vRNA was transfected into 1 × 10 5 S10-3 cells per well of a 12-well cell culture plate using the TransIT-mRNA transfection kit (Mirus Bio LLC, Madison, WI). For cells transfected with the subgenomic replicon p6GLuc ± GAD, medium was changed every 24 hours and harvested for GLuc quantification. Full-length virus p6 was harvested as previously described (35) . HEV focus-forming units were quantified by staining for anti-HEV capsid ORF2. Huh-7.5 cells stably expressing murine restriction factors were infected with DENV (16681 strain) (MOI 0.5), YFV 17D vaccine strain, the parental Asibi strain (MOI 1), and WNV (lineage 1 strain, WNV-TX02) (MOI 0.5). Cells were stained for flow cytometry using the following: rabbit polyclonal anti-NS3 antibody (GeneTex, cat. no. GTX124252, 1:500) for DENV, mouse monoclonal antibody (Santa Cruz Biotechnology, cat. no. SC58083, 1:500) for YFV, and mouse monoclonal anti-NS1 antibody (BEI Resources, cat. no. 10145, 1:500) for WNV.

For RSV F-luc virus production, Hep2 cells (American Type Culture Collection CCL-23) were grown in advanced MEM medium (Thermo Fisher Scientific, Waltham, MA) supplemented with 10% heat-inactivated FCS (Capricorn Scientific, Ebsdorfergrund, Germany), 2 mM l-glutamine (Thermo Fisher Scientific, Waltham, MA), penicillin and streptomycin (100 U/ml; Thermo Fisher Scientific, Waltham, MA), and 1× nonessential amino acids (Thermo Fisher Scientific, Waltham, MA) at 37°C in humidified air with 5% CO 2 . HEp2 cells were seeded in 15-cm cell culture dishes (Corning Incorporated, Life Sciences, Oneonta, NY) to reach 60 to 70% confluence the next day. Twenty-four hours later, medium was removed, and 5 ml of FCS-free advanced minimal essential media (adv. MEM) containing 4 × 10 5 TCID 50 /ml of recombinant human respiratory syncytial virus (HRSV) subtype A F-luc reporter virus (provided by J.-F. Éléöuet) was added. Cells were incubated at 37°C and gently shaken for 4 hours. Medium was replaced with adv. MEM containing 2% FCS followed by further incubation at 37°C until syncytia formation was prominent. Supernatant and cells were harvested, supplemented with 10% of virus stabilizer buffer [1 M MgSO 4 and 0.5 M Hepes (pH 7,5)], and vortexed vigorously for 2 min to release cell-attached virus particles. Debris was removed by centrifugation at 1000g for 5 min, and cell-free supernatant was frozen in −80°C cold ethanol for 12 hours and then transferred to long-term storage at −80°C.

Hepatocytes were isolated from mice by a modified two-step Liberase perfusion (36) . Briefly, mice were anesthetized using Ketamine (Albrecht) and Rompun (Bayer). The body cavity was opened, and a catheter was placed into the portal vein and connected to a flow pump, which pumped media prewarmed at 37°C from a water bath into the catheter, and the vena cava was cut. The liver was first perfused with Earle's balanced salt solution (EBSS) (Gibco) solution containing 0.5 mM EGTA (Sigma-Aldrich) and 10 mM Hepes buffer (Sigma-Aldrich). Subsequently, EBSS supplemented with 10 mM Hepes buffer and Liberase (100 g/ml; Roche) was applied for enzymatic digestion of the tissue at 37°C. After digestion for 10 to 12 min, the liver was carefully disconnected and tissue was manually disrupted with sterile scissors and scalpel in DMEM (Gibco) containing 10% FCS (PAN-Biotech). The suspended hepatocytes were passed through a 100-m nylon filter into 50-ml Falcon tubes. The cell suspensions were centrifuged twice at 300 rpm for 5 min at 4°C, and cell pellets were resuspended in ice-cold DMEM containing 10% FCS. Cell viability was tested by trypan blue (Fluka) before plating on collagen-coated six-well dishes. Approximately 5 × 10 5 cells were plated per well, and supplemented hepatocyte culture media (HCM) (Lonza) were used to maintain primary hepatocytes in culture.

Plated PHHs were obtained from the Department of General, Visceral, and Transplant surgery at Hannover Medical School and cultured as previously reported (37) . Hepatocytes were isolated from liver tissue from donors undergoing partial hepatectomy and were obtained with written informed consent approved by the Ethics Commission of Hannover Medical School (Ethik-Kommission der MHH, no. 252-2008). Again, supplemented HCM media (Lonza) were used to maintain primary hepatocytes in culture.

Initial HCV infection screening of murine hits using F-luc reporter HCV (Jc1) were conducted in 96-well plates (three technical replicates per condition) at MOI 0.1. Subsequent characterization was performed using R-luc reporter HCV (Jc1), again conducted in 96well plates (three technical replicates per condition) at MOI 0.05. A minimum of three biological replicates were performed for all experiments. For HCV infection of plated murine hepatocytes, 5 × 10 5 TCID 50 units per six-well dish were used for WT Jc1 or p100pop virus. Viral supernatant was collected each day and replaced with fresh HCM media containing 10 M ruxolitinib (AdipoGen, Leistel, Switzerland). The viral supernatants were then tested for infectious viral particle production using the TCID 50 assay.

Immunofluorescence and imaging of PMHs and Huh-7.5 cells overexpressing restriction factors were performed as follows. PMHs were seeded on collagen-coated glass coverslips in 24-well dishes. Huh-7.5 cells overexpressing murine Cd302 or Cr1l were seeded on uncoated glass coverslips (5 × 10 4 cells per well) and grown until they reached about 80% confluence. Fixation was achieved by incubating the cells in chilled (4°C) 95% ethanol + 5% acetic acid for 10 min at room temperature. After two washes in PBS, cells were permeabilized for 10 min at room temperature in PBS + 0.1% Triton X-100 and rinsed twice again in PBS. To block potential nonspecific antibody binding, coverslips were incubated in a 5% solution of goat serum in PBS for 1 hour at room temperature. To detect murine Cd302, 5 g/ml of an -Cd302 monoclonal (Cd302/Clec13a; R&D Systems, rat IgG1) was used. To detect murine Cr1l, a polyclonal antibody solution at a concentration of 2 g/ml (Crry M180; Santa Cruz Biotechnology, rabbit IgG1) was used. Incubation of these solutions was performed at room temperature for 1 hour or overnight at 4°C. After three washes in PBS, the primary antibodies were detected by fluorophore-conjugated anti-rat [Alexa Fluor 488 rabbit anti-rat immunoglobulin G (IgG); Life Technologies] and anti-rabbit [Alexa Fluor 568 donkey anti-rabbit IgG (H + L), Invitrogen] antibodies, respectively, at a concentration of 2 g/ml in blocking solution for 1 hour at room temperature and protected from light. After washing off excess secondary antibodies with PBS twice for 5 min, staining of the nuclei was performed using a 0.5-g/ml 4′,6-diamidino-2-phenylindole (DAPI) solution in H 2 O. One final wash in H 2 O was then followed by mounting of the coverslips in ProLong Gold Antifade Mountant (Thermo Fisher Scientific) and drying overnight at room temperature protected from light. For imaging, an inversed confocal laser scanning microscope (Olympus FluoView 1000) with a ×100 magnification objective was used with FluoView 1000 imaging software (Olympus). Microscope settings, including laser intensity and exposure time, were identical for the target protein (Cd302 or Cr1l), the isotype control, and the secondary only control, respectively.

Matrigel-polarized organoids were infected with DiD-HCV, incubated on ice for an hour, then transferred to 37°C (time of temperature shift: t = 0), and fixed in 3.6% paraformaldehyde (PFA) at various points post-temperature shift. Cells were fixed for 20 min in PFA, permeabilized with 1% Triton X-100/PBS for 10 min, washed with 0.1 M glycine in PBS three times for 10 min each, and then incubated in blocking solution for 2 hours (wash buffer: 0.1% bovine serum albumin, 0.2% Triton X-100, and 0.005% Tween 20 in PBS + 20% goat serum). Samples were incubated at 4°C overnight with anti-ZO-1 antibody (1:500; Invitrogen) and then allowed to reform at room temperature for 10 min. Samples were washed three times for 20 min each time, with wash buffer, and then incubated for 1 hour at room temperature with Alexa Fluor-conjugated secondary antibody (488) in blocking solution. Coverslips were washed three times as above and then mounted on slides with DAPI prolong gold (Invitrogen). Slides were imaged using an Olympus Disk Scanning Unit Spinning Disc Confocal with a 100× numerical aperture 1.45 oil-immersion objective and Hamamatsu back thinned electron multiplying charge-coupled device camera; images were captured using SlideBook imaging software; intensification was set to 255, and z-stacks of the organoids were acquired with 0.3-m slices. After acquisition, images were quantified for colocalization in ImageJ with RGB profiler (C. Laummonerie) and colocalization highlighter. Images were selected from z-stack slices, separated into channels, adjusted for contrast and brightness, smoothed, and finally reassembled.

For the detection of Cr1l (Crry) in formalin-fixed and paraffinembedded murine tissue, the antibody sc30214 (Santa Cruz Biotechnology) was diluted 1:400, and antigen retrieval was performed by 20′ microwave/citrate cooking. As a negative control, the primary antibody was replaced in the same concentration with rabbit serum, and for all slides, a biotinylated goat anti-rabbit secondary antibody was used. For visualization, 3,3′-diaminobenzidine was applied.

A confluent monolayer of cells was detached using trypsin with the exception of PMHs, which were detached using EDTA (1 mM). Cells were pelleted and subsequently resuspended in FACS buffer (1% FCS in PBS). Approximately 1 × 10 6 Huh-7.5 cells or CHO-745 cells overexpressing mouse restriction factors or PMHs endogenously expressing these factors were stained for 30 min at 4°C with unconjugated primary monoclonal antibodies specific for Cd302 (Cd302/Clec13a; R&D Systems, rat IgG1) and Cr1l (Crry M180; Santa Cruz Biotechnology, rabbit IgG1 or anti-Cr1l biorbyt and rabbit IgG) diluted in FACS buffer to 1.6 g/ml. To analyze the endogenous expression of human receptors present on Huh 7.5 cells, primary unconjugated antibodies specific for scavenger receptor class B type 1 (Novus; polyclonal rabbit antibody), Claudin 1 (R&D Systems; rat IgG), and OCLN (Life technologies; mouse IgG) were diluted in FACS buffer to 20, 10, and 1 g/ml, respectively. For CD81, directly coupled antibody to fluorescein isothiocyanate (FITC) was used (BD Pharmingen, JS-81). Subsequently, cells were washed with FACS buffer thrice, and bound antibodies were detected by incubation for 30 min at 4°C with specific secondary antibody conjugated to an Alexa Fluor (Life Technologies), namely, anti-mouse Alexa Fluor 488, anti-rabbit Alexa Fluor 647, and anti-mouse Alexa Fluor 647 at a dilution of 1:1000 in FACS buffer and rat-specific secondary antibody conjugated to phycoerythrin (eBioscience) at a dilution of 1:200 in FACS buffer. The following isotype controls were used: rat isotype IgG 1 (R&D Systems), rabbit polyclonal (Abcam), and isotype FITC mouse IgG1 (BD Pharmingen) at the same concentration as primary antibodies. Stained cells were washed with FACS buffer thrice, resuspended in FACS buffer, and analyzed immediately using an Accuri C6 cytometer (BD Biosciences), and data were analyzed using FlowJo software (Tree Star).

The Huh-7.5 N-HA-HA-L-Cd302/Cr1l cell line was obtained by lentiviral transduction of Huh-7.5 cells with the pWPI-N-HA-HA-L-Cd302 plasmid, selection with blasticidin (5 g/ml) and subsequent lentiviral transduction of the pWPI-Cr1l plasmid, followed by a double selection with blasticidin and puromycin (2.5 g/ml). To test the interaction between Cd302 and Cr1l, half a confluent 15-cm dish of Huh-7.5/empty, Huh-7.5/Cr1l, or Huh-7.5 N-HA-HA-L-Cd302/Cr1l cells was harvested by trypsinization and lysed in 250 l of IP buffer [50 mM Hepes (pH 7.4), 150 mM NaCl, 1 mM CaCl 2 , 10% glycerol, 1% NP-40, and complete EDTA-free protease inhibitor cocktail 1× (Roche no. 04 693 124 001)] for 30 min on ice. Cell nuclei were removed by centrifugation (10 min at 20,000g), and 5 l of the supernatant was kept as an input for the Western blot. The anti-HA resin (Sigma-Aldrich; A2095) was washed twice in PBS (30 s at 12,000g), and 25 l was used per IP. Cleared lysates and resin were incubated together overnight on a rotating wheel at 4°C. Afterward, the beads were washed twice quickly (no incubation time), twice with 5-min incubation periods on a rotating wheel, and once quickly with IP buffer (without protease inhibitor). After a final quick wash in water, the proteins were eluted in reducing Laemmli buffer (7 min at 70°C) and loaded on an SDS-polyacrylamide gel electrophoresis for separation and transfer on a polyvinylidene difluoride membrane. The membrane was probed with rat anti-Cd302 antibody (1/250) and rabbit anti-Cr1l antibody (1/250), followed by the secondary goat anti-rat IRDye 800CW and donkey anti-rabbit IRDye680RD (both at 1/15,000; LI-COR). Signal intensities were read with the Odyssey CLx imager (LI-COR).

Total cellular RNAs from cell lines or primary cells were isolated using a NucleoSpin RNA Kit (Macherey Nagel) according to the manufacturer's instructions. Total RNA concentrations were quantified using a NanoDrop spectrophotometer (PEQLAB). Subsequently, 500 ng to 1 g of total RNA was reverse-transcribed into cDNA using a PrimeScript First Strand cDNA Synthesis Kit (Takara) in accordance with the kit instructions. Reactions were performed in triplicate. Subsequent qPCR of cDNAs was performed using ×2 SYBR MasterMix (Takara) and the LightCycler 480 system (Roche). Validated primer pairs for all mRNAs were taken from PrimerBank (https://pga.mgh.harvard.edu/primerbank/). For quantification of fold regulation in gene expression, calculations were performed using the  CT method (QIAGEN Data Analysis Center: https://www. qiagen.com/de/shop/genes-and-pathways/data-analysis-centeroverview-page/). For normalization, ACTB and HPRT were used as reference genes.

Cells were washed with PBS and lysed in radioimmunoprecipitation buffer [0.3 M NaCl, 20 mM tris-HCl (pH 8), 1% sodium deoxycholate, 0.1% SDS, and 1% Triton X-100] for 30 min on ice. Total protein content was determined by Bradford assay. Equal protein amounts for each sample were mixed with 2× denaturing protein sample buffer [200 mM tris-HCl (pH 8.8), 5 mM EDTA, 0.1% bromophenol blue, 10% sucrose, 3.3% SDS, and 2% 2-mercaptoethanol], heated for 5 min at 98°C, loaded onto a 11% SDS gel, and resolved by electrophoresis. Subsequently, proteins were transferred to a polyvinylidene difluoride membrane, which was then blocked with 5% milk in PBS containing 0.5% Tween 20 for 1 hour at room temperature. The membrane was then incubated with either -mCrry/mCr1l (1:250; Santa Cruz Biotechnology), -mCd302 (1:250; R&D Systems), or --actin (1:1000; Sigma-Aldrich) followed by incubation with secondary antibody coupled to horseradish peroxidase (Sigma-Aldrich). Bound antibodies were detected with the ECL Plus Detection System (GE Healthcare).

Retroviral pseudoparticles were generated with surface glycoproteins derived from HCV E1E2 (isolates Con1, genotype 1b, or UKN2B2.8, genotype 2b) or an empty vector as negative control (pcDNA EMPTY). Packaging construct pHIT60 encoding MLV gag/pol was cotransfected with the retroviral vector (pRV-F-Luc) and the individual envelope expression constructs using polyethylenimine (PEI) (Polyplus, Illkirch, France). Twenty-four hours later, sodium butyrate (10 mM) was added to transfected cells and incubated for 6 to 8 hours. At 48 hours after transfection, virus-containing culture fluids were harvested, filtered through a 0.45-m pore size filter (VWR International, USA), and used to inoculate target cells.

Murine hepatocytes plated in six-well dishes were harvested after infection via aspiration of media, washed three times in PBS, and lysed via addition of 300 l of 1% Triton X-100 in PBS with added protease inhibitor (Roche). Lysates were subsequently diluted in 1% Triton X-100 in PBS, and cell-associated HCV core was quantified by an automated chemiluminescent microparticle immunoassay (Architect HCV Ag, Abbott, Germany).

Phylogenetic analysis of mammalian Cd302 sequences was performed using the maximum likelihood method implemented in MEGA7 (38) based on the data-specific model. The significance of groupings was assessed using the bootstrap approach with 1000 pseudoreplicates performed. The tree with the highest log likelihood is presented, with significant bootstrap values (70%) assigned to the corresponding branch. The tree was generated under a GTR +  + I model of substitution whereby discrete Gamma distribution () was used to model evolutionary rate differences among sites (four rate categories). The proportion of invariant sites (I) was also incorporated into the reconstruction. The phylogeny is drawn to scale, with branch lengths proportional to the number of substitutions per site. All positions containing gaps and missing data were eliminated from the analysis. The dataset incorporated Cd302 sequences from 24 species, and a total of 603 nucleotide positions were included in the final analysis.

Canonical pathway analyses were performed using IPA (QIAGEN). Data input consisted of an Excel sheet containing Ensembl identifiers, P values, FDR P values, fold change, and log fold change values for genes, as previously determined with CLC Genomics Workbench. In general, default settings were used for all categories, but species was set to "human" for data from Huh-7.5 cells ectopically expressing murine factors and "mouse" for data from PMHs. FDR P value significance threshold was set to 0.05 for genes included in the subsequent analysis. Z scores were calculated on the basis of the expression fold change.

Mice with hepatocyte-specific expression of human occludin and Cd81 (hOC hep , hOCLN +/− hCD81 +/− ) were generated by breeding hOC con mice with AlbCre mice (39). hOC con mice comprise an inverted, Cre-activatable expression cassette for human occludin and CD81 and were generated upon Flp-based targeted integration of the Rosa26 locus (40) using the following targeting cassette: Fwt -IPS-RFP -P CAGGS -loxL3-loxP-(hOCLN-IRES-hCD81) inv -loxL3 inv -loxP inv -IRES -F5. Knockout of Cd302 (Cd302 −/− ) was achieved by CRISPR-Cas9-mediated excision of 40 bp including the initiation codon (c − 29) − (c + 11) in C57BL/6 zygotes using guide RNA target sites CACCCGACAAGCACCGCCCC and TGCACTCTCCGGG-GCGCGGC, applying a previously published protocol (41) . hOC hep Cd302 −/− animals were generated by breeding. Genetically modified mice were generated with the approval of the ethical board of the Lower Saxony State Office for Consumer Protection and Food Safety, Oldenburg, Germany.

CHO binding assay CHO-745 cells were either left untransfected or PEI-transfected with pWPI-SCARB1, pWPI-mCd302, pWPI-mCr1l, or both pWPI-mCd302 and pWPI-mCr1l together. Cell surface expression levels were analyzed 48 hours after transfection using FACS. At 48 hours after transfection, CHO-745 cells were incubated with HCVcc (Jc1) particles for 2 hours at 37°C. After binding, the cells were washed extensively with PBS, total RNA-isolated, and HCV RNA-quantified using RT-qPCR.

In vivo infections hOC hep or hOC hep Cd302 −/− mice were inoculated intrasplenically with 100 l of concentrated DMEM containing 1.2 × 10 7 TCID 50 units of HCV p100pop virus. Ruxolitinib treatment was orally administered every 8 to 12 hours (starting 4 hours before infection) at a dose of 100 mg/kg, and ruxolitinib (Ambeed, IL, USA) was dissolved in 20% dimethyl sulfoxide (DMSO) and 50% PEG 400 (seven doses for animals tested for 3 days and 13 doses for animals tested for 5 days). At the end of each experiment, animals were euthanized, and blood and liver samples were processed for further analysis. All procedures were performed according to European and Belgian legislation and were approved by the Animal Ethics Committee of the Faculty of Medicine and Health Sciences of Ghent University. Snap-frozen whole or partial livers from individual mice were homogenized in RA1 lysis buffer from the Macherey Nagel NucleoSpin RNA Isolation kit at a concentration of 100 mg/ml. Total RNA extraction was then performed on 350 l according to the manufacturer's instructions. To further enrich viral RNA, an HCV capture assay was performed whereby 10 g of extracted total RNA was diluted in 200 l of TEN buffer [10 mM tris-HCl (pH 8.0), 1 mM EDTA, and 100 mM NaCl] and incubated for 5 min at 75°C with subsequent addition of 0.5 g of HCV-specific biotinylated capture DNA (BIOTEG-AAG TAT ACT CCG CCA ACG ATC TGG CCG CCG) followed by vortexing and further incubation for 5 min at 65°C. Meanwhile, MACS columns were equilibrated according to the manufacturer's instructions (MACS Streptavidin Kit, Miltenyi Biotec). One hundred microliters of MACS streptavidin microbeads was then added to the mix and incubated for further 2 min at 65°C. The solution was then added to the MACS columns and washed with 5 × 200 l with TE buffer [10 mM tris-HCl (pH 8.0) and 1 mM EDTA], and captured RNA was then eluted with 150 l of H 2 O preheated to 80°C. Drops 2 to 4 were collected (approximately 50 l) for analysis by RT-qPCR. Captured RNA from the liver samples were analyzed by RT-qPCR using the Roche LightCycler 480 RNA Master Hydrolysis Probes kit (Roche), primers (5′-TCTGCGGAACCGGTGAGTA-3′ and 5′-GGGCAT-AGAG TGGGTTTATCCA-3′) and probe (5′-6FAM-AAAGGAC-CCAGTCTTCCCGGCAA-TMR-3′), according to the manufacturer's conditions.

A homology model of the extracellular domain of mCd302 was generated on the basis of the NMR structure of the hCD302 extracellular domain [Protein Data Bank (PDB) 2NAN] using the Phyre2 web server (42) . Nonconserved residues were mapped on the surface of mCd302 according to a pairwise sequence alignment obtained via Clustal Omega (43) . Structure figures were prepared with PyMOL (The PyMOL Molecular Graphics System, version 1.8.0.3, Schrödinger, LLC).

Statistical tests were performed in GraphPad Prism v8.0 on data generated from biological experiments, with appropriate correction for multiple comparisons: ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05. Statistical analysis of DEGs from RNA-seq experiments was performed in CLC Genomics Workbench with FDR or Bonferroni correction for multiple comparisons.

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/6/45/eabd3233/DC1 View/request a protocol for this paper from Bio-protocol.

A cross-species view on viruses

Decoding type I and III interferon signalling during viral infection

How host genetics dictates successful viral zoonosis

Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses

Immune protection against reinfection with nonprimate hepacivirus

Mouse models of acute and chronic hepacivirus infection

Viral persistence, liver disease, and host response in a hepatitis C-like virus rat model

Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells

Completion of the entire hepatitis C virus life cycle in genetically humanized mice

A genetically humanized mouse model for hepatitis C virus infection

Creation and characterization of a cell-death reporter cell line for hepatitis C virus infection

Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication

SEC14L2 enables pan-genotype HCV replication in cell culture

Single particle imaging of polarized hepatoma organoids upon hepatitis C virus infection reveals an ordered and sequential entry process

Animal cell mutants defective in glycosaminoglycan biosynthesis

Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

The novel endocytic and phagocytic C-Type lectin receptor DCL-1/CD302 on macrophages is colocalized with F-actin, suggesting a role in cell adhesion and migration

Characterization of the expression and function of the C-type lectin receptor CD302 in mice and humans reveals a role in dendritic cell migration

Interferome v2.0: An updated database of annotated interferon-regulated genes

Distinct poly(I-C) and virus-activated signaling pathways leading to interferon- production in hepatocytes

Impacts of the cretaceous terrestrial revolution and KPg extinction on mammal diversification

The C-type lectin-like domain superfamily

Chmelík, 1 H, 13 C and 15 N resonance assignments of human DCL-1 (CD302) extracellular domain

Response of hepatitis C virus to long-term passage in the presence of alpha interferon: Multiple mutations and a common phenotype

A critical role for murine complement regulator crry in fetomaternal tolerance

Retinoid X receptor  attenuates host antiviral response by suppressing type I interferon

Nuclear receptors control pro-viral and antiviral metabolic responses to hepatitis C virus infection

C-type lectins: Their network and roles in pathogen recognition and immunity

Comprehensive comparative analysis of strand-specific RNA sequencing methods

RNA interference and single particle tracking analysis of hepatitis C virus endocytosis

Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination

Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin

Epidermal growth factor improves lentivirus vector gene transfer into primary mouse hepatocytes

Explanted diseased livers-A possible source of metabolic competent primary human hepatocytes

MEGA7: Molecular evolutionary genetics analysis version 7.0 for bigger datasets

Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic  cell-specific gene knock-outs using Cre recombinase

Strict control of transgene expression in a mouse model for sensitive biological applications based on RMCE compatible ES cells

Efficient generation of Rosa26 knock-in mice using CRISPR/Cas9 in C57BL/6 zygotes

The Phyre2 web portal for protein modeling, prediction and analysis

Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega

Bukh for the pan-genotypic panel of JFH-1-based chimeras

Bieniasz for the lentiviral vector pV1

Evans for sharing his library generation protocol

Ball for HCV E1E2 plasmid UKN2B2.1

Heim for providing IFN-treated mouse livers

German Research Foundation) within project B10 of CRC 900-project 158989968. T.P. was funded by a grant from the European Research Council ERC-2011-StG_281473-(VIRAFRONT)

Author contributions: Conceptualization

Additional data related to this paper may be requested from the authors. Raw and processed RNA-seq data generated in this study are submitted to the NCBI GEO database (GEO accession number GSE140591). RNA-seq data from Huh-7.5 cells transduced with a control EMTPY lentivirus are reported in Tegtmeyer and Vieyres (manuscript in revision: accession number GSE132548). Transgenic knockout mice generated in this study are available from the authors under a material transfer agreement

Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice

We thank the following people for their contribution of reagents and infrastructure that greatly enhanced this study: HZI Braunschweig GMAK facility, including R. Geffers, M. Jarek, S. Bhuju, and M. Scharfe for generating RNA-seq data; HZI Braunschweig TGSM transgenic for generation of genetically modified mice and the Central Animal Facility for mouse housing; the MHH Diagnostics and T. Schultz and his team for diagnostic core